We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+632.23%
AUM
$24.1B
AUM Growth
+$1.97B
Cap. Flow
+$2.04B
Cap. Flow %
8.47%
Top 10 Hldgs %
10.49%
Holding
3,709
New
1,117
Increased
953
Reduced
622
Closed
747

Sector Composition

Rank Sector Weight
1 Healthcare 20.28%
2 Financials 16.56%
3 Technology 13.74%
4 Consumer Discretionary 11.01%
5 Communication Services 4.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRK icon
2801
Merck
MRK
$322B
$189K ﹤0.01%
+2,514
New +$191K
NPTN
2802
DELISTED
NEOPHOTONICS CORP
NPTN
$189K ﹤0.01%
21,648
-18,137
-46% -$165K
MOD icon
2803
Modine Manufacturing
MOD
$10.5B
$187K ﹤0.01%
+16,543
New +$231K
BSET icon
2804
Bassett Furniture
BSET
$170M
$186K ﹤0.01%
+10,290
New +$226K
BWEN icon
2805
Broadwind
BWEN
$125M
$186K ﹤0.01%
71,798
+50,111
+231% +$176K
KOPN icon
2806
Kopin
KOPN
$964M
$186K ﹤0.01%
36,171
-66,728
-65% -$405K
LXU icon
2807
LSB Industries
LXU
$719M
$186K ﹤0.01%
+23,706
New +$148K
AXP icon
2808
CALL
American Express
AXP
$230B
$184K ﹤0.01%
1,100
+1,000
+1,000% +$167K
LVOX
2809
DELISTED
LiveVox Holding, Inc. Class A Common Stock
LVOX
$183K ﹤0.01%
28,110
-944
-3% -$6.82K
NBSE
2810
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$182K ﹤0.01%
2,516
-4,305
-63% -$329K
LOGC
2811
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$181K ﹤0.01%
39,523
-1,045
-3% -$4.6K
RFP
2812
DELISTED
Resolute Forest Products Inc.
RFP
$179K ﹤0.01%
+15,046
New +$176K
DENN
2813
DELISTED
Denny's
DENN
$176K ﹤0.01%
+10,753
New +$169K
ZYXI
2814
DELISTED
Zynex
ZYXI
$172K ﹤0.01%
+16,658
New +$214K
LRCX icon
2815
PUT
Lam Research
LRCX
$390B
$171K ﹤0.01%
3,000
+2,000
+200% +$122K
CZOO
2816
DELISTED
Cazoo Group Ltd
CZOO
$171K ﹤0.01%
11
-133
-92% -$2.49M
CLIM.WS
2817
CALL
DELISTED
Climate Real Impact Solutions II Acquisition Corporation Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
CLIM.WS
$171K ﹤0.01%
17,495
LIND icon
2818
Lindblad Expeditions
LIND
$2.15B
$170K ﹤0.01%
+11,677
New +$164K
PLG
2819
Platinum Group Metals
PLG
$194M
$167K ﹤0.01%
+83,091
New +$230K
FRBA icon
2820
First Bank
FRBA
$458M
$166K ﹤0.01%
11,801
-8,533
-42% -$114K
PBYI icon
2821
Puma Biotechnology
PBYI
$453M
$163K ﹤0.01%
+23,276
New +$174K
MTAL.U
2822
DELISTED
Metals Acquisition Corp Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant
MTAL.U
$162K ﹤0.01%
+16,333
New +$162K
BON
2823
Bon Natural Life
BON
$9.35M
$158K ﹤0.01%
+75
New +$208K
MMM icon
2824
CALL
3M
MMM
$94.4B
$158K ﹤0.01%
+1,076
New +$174K
KRE icon
2825
State Street SPDR S&P Regional Banking ETF
KRE
$4.61B
$157K ﹤0.01%
2,312
-80,277
-97% -$5.16M

Similar funds

Marshall Wace's Q3 2021 Portfolio in Review

As of Q3 2021, Marshall Wace held 3,709 positions worth $24.1B, up 8.9% from $22.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace deployed $2.04B of net new capital in Q3 2021, opening 1,117 new positions and adding to 953 existing holdings. Its largest new stake was SkinHealth Systems: 4,113,430 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Biogen, an estimated $210M trimmed.

  • Marshall Wace's largest Q3 2021 buy was SkinHealth Systems: 4,113,430 shares worth $107M.
  • Marshall Wace added most to Uber in Q3 2021, an estimated $127M increase.
  • Marshall Wace's biggest Q3 2021 reduction was Biogen, cutting an estimated $210M.
  • Marshall Wace fully exited Vipshop in Q3 2021, selling an estimated $58.7M.
  • Marshall Wace's ten largest holdings make up 10% of its $24.1B portfolio in Q3 2021.
  • Marshall Wace opened 1,117 new positions and closed 747 in Q3 2021.
  • Marshall Wace's portfolio value rose 8.9% quarter-over-quarter to $24.1B.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.